Case Study | September 17, 2009| Igor F. Palacios, M.D., Roberto J. Cubeddu, M.D. , Christian Witzke, M.D., Angel Caldera, M.D.

Left Main PCI Using LV Support With the Impella 2.5

The Impella 2.5 catheter

The Impella 2.5 is inserted percutaneously in the cath lab via the femoral artery into the left ventricle and provides up to 2.5 liters of blood per minute from the left ventricle into the ascending aorta.

A 55-year-old woman with a history of heavy alcohol use, hepatitis C induced cirrhosis, hypertension, and chronic renal insufficiency presented at Massachusetts General Hospital in Boston Mass., with nine months of increasing intermittent substernal chest pressure. The pain was inducible by exertion, was nonradiating, and when present associated with shortness of breath, and diaphoresis.

Coronary angiogram showed complex multivessel coronary artery disease. The left main (LM) had a high-grade 90 percent calcified, eccentric stenosis involving the distal vessel segment and extending into the ostium and proximal left anterior descending (70 percent stenosis) and left circumflex (98 percent stenosis) bifurcating coronary arteries.

The patient was evaluated for coronary artery bypass graft, but due to her high surgical risk, poor vein mapping and persistently elevated serum amylase and lipase levels, she was considered a poor candidate. Consensus was made to proceed with high-risk percutaneous coronary intervention (PCI) using the Impella 2.5 cardiac support system.

The Impella is a percutaneously-placed left ventricular support device that provides up to 2.5 liters per minutes of forward flow from the left ventricle (LV) directly into the ascending aorta. The 12 Fr. pump is mounted on the distal end of a 9 Fr. catheter and connected to the Impella Mobile Console.

Transesophageal echocardiography (TEE) was performed prior to the procedure. Findings included a normal LV size and function with evidence of false tendon. There was symmetric LV hypertrophy, mild segmental LV dysfunction involving the inferior wall, a LV true aneurysm at the base of the inferior wall with no evidence of LV thrombus. The estimated ejection fraction was 76 percent.

The left common femoral artery was accessed using a modified Seldinger technique, and upsized to a 12 Fr. sheath to accomodate the Impella catheter. The system was initiated and set at a performance level P8. Heparin was administered to maintain the patient’s activated clotting time above 250. Rotational atherectomy (Rota-blator) was successfully performed from the LM into the LCX artery. Kissing bare metal stents where then subsequently delivered from the LM into the LAD and LCX. Post-stenting kissing balloon angioplasty was then performed with excellent results. The Impella sustained adequate hemodynamic levels throughout the procedure and delivered an average flow of up to 2.1 liters per minute. The mean aortic pressure was maintained around 103 ±3mmHg throughout the procedure, while the mean pulmonary artery pressure averaged 24 to 34mmHg. Immediately following PCI, the Impella was weaned off in stepwise fashion, until it was turned off and removed. Vascular access sheaths were pulled and hemostasis obtained using manual compression. The patient is now chest pain free and attending cardiac rehab.

“This report highlights the valuable use of the 2.5 Impella device in patients with complex high-risk PCI where the alternative surgical revascularization strategy may be otherwise prohibitive or simply too high of risk,” said Roberto J. Cubeddu, M.D., interventional cardiologist at Massachusetts General. “The Impella circulatory support system provides the critical continuous systemic and coronary perfusion time necessary to deliver the preferred utmost complex interventional strategy safely and effectively.”

“Impella allows the interventionalist confidence to be able to use PCI in cases that might otherwise be destined to have a very prolonged and complicated hospital course had they gone to operative therapy,” said Abiomed Medical Director Daniel H. Raess, M.D. “It is notable that in many institutions, some of the most vocal proponents for Impella support are in fact the cardiac surgeons.”

Related Content

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Overlay Init